LAUSR

About LAUSR
Donate
Contact Us

Follow us:

You are not signed in:

Sign Up!


   Articles with "jak2v617f" as a keyword



Photo from wikipedia

Estimation of diagnosis and prognosis in ET by assessment of CALR and JAK2V617F mutations and laboratory findings: a meta-analysis

Sign Up to like & get
recommendations! Published in 2017 at "Clinical and Translational Oncology"

DOI: 10.1007/s12094-017-1618-1

Abstract: BackgroundEssential thrombocythemia (ET) is a benign disease with slow progress in which thrombosis is a cause of mortality. JAK2V617F and calreticulin (CALR) are the most frequent mutations in this disease. In this systematic review and… read more here.

Keywords: jak2v617f; diagnosis; prognosis; calr ... See more keywords
Photo from wikipedia

DISTINCT EFFECTS OF RUXOLITINIB AND INTERFERON-ALPHA ON JAK2V617F MYELOPROLIFERATIVE NEOPLASM HEMATOPOIETIC STEM CELL POPULATIONS

Sign Up to like & get
recommendations! Published in 2019 at "Experimental Hematology"

DOI: 10.1016/j.exphem.2019.06.335

Abstract: Myeloproliferative neoplasms (MPN) arise from the acquisition of genetic mutations in hematopoietic stem cells. Currently, patients receive treatment with cytotoxic agents, the JAK1/2 inhibitor, ruxolitinib, or pegylated forms of interferon alpha (IFN-α). Ruxolitinib is highly… read more here.

Keywords: jak2v617f; treatment; stem; cell ... See more keywords
Photo by bneale87 from unsplash

Essential thrombocytemia following immune thrombocytopenia with JAK2V617F mutation

Sign Up to like & get
recommendations! Published in 2018 at "Leukemia Research Reports"

DOI: 10.1016/j.lrr.2017.12.002

Abstract: JAK2V617F mutation is found in about 60% of cases of essential thrombocytemia (ET) and represents a driving mutation. Immune thrombocytopenia (ITP) is an autoimmune disease characterized by a low platelet (PLT) count. So far, only… read more here.

Keywords: jak2v617f; jak2v617f mutation; essential thrombocytemia; immune thrombocytopenia ... See more keywords
Photo from wikipedia

JAK2V617F but not CALR mutations confer increased molecular responses to interferon-α via JAK1/STAT1 activation

Sign Up to like & get
recommendations! Published in 2018 at "Leukemia"

DOI: 10.1038/s41375-018-0295-6

Abstract: Pegylated interferon-α (peg-IFNa) treatment induces molecular responses (MR) in patients with myeloproliferative neoplasms (MPNs), including partial MR (PMR) in 30–40% of patients. Here, we compared the efficacy of IFNa treatment in JAK2V617F- vs. calreticulin (CALR)-mutated… read more here.

Keywords: jak2v617f; jak1 stat1; molecular responses; calr mutated ... See more keywords

Reversine exhibits antineoplastic activity in JAK2V617F-positive myeloproliferative neoplasms

Sign Up to like & get
recommendations! Published in 2019 at "Scientific Reports"

DOI: 10.1038/s41598-019-46163-2

Abstract: JAK2/STAT signaling participates in the Ph-negative myeloproliferative neoplasms (MPN) pathophysiology and has been targeted by ruxolitinib, a JAK1/2 inhibitor. In the present study, the impact of ruxolitinib treatment on cytoskeleton-related genes expression was explored. In… read more here.

Keywords: jak2v617f; set2 cells; reversine; expression ... See more keywords
Photo by philinit from unsplash

JAK2V617F Is a Risk Factor for TIA/Stroke in Young Patients.

Sign Up to like & get
recommendations! Published in 2022 at "Thrombosis and haemostasis"

DOI: 10.1055/s-0042-1743470

Abstract: The objective of this study was to assess the risk of arterial thrombosis in patients who harbor the JAK2V617F allele burden ≥1% detected during workup for myeloproliferative neoplasms (MPNs). We conducted a large cross-sectional analysis… read more here.

Keywords: jak2v617f; tia stroke; age; risk factor ... See more keywords
Photo by tomspentys from unsplash

Frequency of JAK2V617F, MPL and CALR driver mutations and associated clinical characteristics in a Norwegian patient cohort with myeloproliferative neoplasms

Sign Up to like & get
recommendations! Published in 2022 at "Scandinavian Journal of Clinical and Laboratory Investigation"

DOI: 10.1080/00365513.2022.2150984

Abstract: Abstract Myeloproliferative neoplasms are hematological disorders characterized by increased production in one or more myeloid cell lines, associated with driver mutations in JAK2-, MPL- and CALR-genes. The aims of this study were to investigate the… read more here.

Keywords: calr; jak2v617f; patient cohort; driver mutations ... See more keywords
Photo by dawson2406 from unsplash

Molecular analysis of phenotypic heterogeneity in JAK2V617F‐positive myeloproliferative neoplasms reveals a potential target for therapy

Sign Up to like & get
recommendations! Published in 2023 at "British Journal of Haematology"

DOI: 10.1111/bjh.18669

Abstract: JAK2V617F is the most frequent mutation in BCR‐ABL‐negative myeloproliferative neoplasms (MPNs). It is an important but not the only determinant of MPN phenotype. We performed high‐throughput sequencing on JAK2V617F+ essential thrombocythaemia (ET) and polycythaemia vera… read more here.

Keywords: jak2v617f; wnt catenin; analysis; phenotypic heterogeneity ... See more keywords
Photo by sharonmccutcheon from unsplash

SLAMF7high CD16negative Monocytes Increase in Peripheral Blood of Patients with Myelofibrosis in Correlation with JAK2V617F Mutation

Sign Up to like & get
recommendations! Published in 2018 at "Blood"

DOI: 10.1182/blood-2018-99-110916

Abstract: Introduction Myelofibrosis (MF) occurrence can be attributed to various pathogenic mechanisms. A recent study showed that the neoplastic clone of fibrocytes (spindle shaped, fibroblast-like blood cells derived from monocyte lineage) was essential in primary MF… read more here.

Keywords: cd16; jak2v617f; mpn patients; research funding ... See more keywords
Photo by thinkmagically from unsplash

The High Mobility Group A1 Chromatin Regulator Is Required for Pathologic Megakaryocyte Development and Progression to Myelofibrosis in JAK2V617F Murine Models

Sign Up to like & get
recommendations! Published in 2019 at "Blood"

DOI: 10.1182/blood-2019-131432

Abstract: Introduction: JAK2V617F-positive myeloproliferative neoplasms (MPN) are clonal hematopoietic stem cell (HSC) disorders characterized by unregulated JAK2/STAT signaling and increased risk of transformation to myelofibrosis (MF). Pathologic JAK2/STAT signaling of the thrombopoietin/thrombopoietin receptor pathway in HSC,… read more here.

Keywords: jak2v617f; model; hmga1; progression ... See more keywords
Photo by jan_huber from unsplash

TGF-β Signaling Contributes to the Clonal Dominance of Jak2V617F Hematopoietic Stem/Progenitor Cells

Sign Up to like & get
recommendations! Published in 2020 at "Blood"

DOI: 10.1182/blood-2020-139638

Abstract: Increased TGF-β expression in the bone marrow microenvironment is present in most cases of myeloproliferative neoplasms (MPNs), however, its contribution to disease pathogenesis is not well understood. Multiple prior studies show that TGF-β suppresses the… read more here.

Keywords: jak2v617f; tgf signaling; jak2v617f hspcs; tgf ... See more keywords